Depression is associated with systemic inflammation. In animals, systemic inflammation can induce neuroinflammation and activation of microglia; however, postmortem studies have not convincingly shown that there is neuroinflammation in depression. The purpose of this study was to use positron emission tomography (PET) with [ 11 C]PBR28, which binds to the neuroinflammation marker translocator protein 18 kDa (TSPO), to compare the level of TSPO between individuals with depression and control subjects. Ten individuals who were in an acute episode of major depression and 10 control subjects matched for TSPO genotype and other characteristics had a PET scan with arterial input function to quantify levels of TSPO in brain regions of interest (ROIs). Total volume of distribution (V T ) of [ 11 C]PBR28 was used as a measure of total ligand binding. The primary outcome was the difference in V T between the two groups; this was assessed using a linear mixed model with group as a between-subject factor and region as a within-subject factor. There was no statistically significant difference in [ 11 C]PBR28 binding (V T ) between the two groups. In fact, 7 of 10 individuals with depression had lower [ 11 C]PBR28 binding in all ROIs compared to their respective genotype-matched control subjects. Future studies are needed to determine whether individuals with mild-to-moderate depression have lower TSPO levels and to assess whether individuals with severe depression and/or with elevated levels of systemic inflammation might have higher TSPO levels than control subjects.
t r a c t
Depression is associated with systemic inflammation. In animals, systemic inflammation can induce neuroinflammation and activation of microglia; however, postmortem studies have not convincingly shown that there is neuroinflammation in depression. The purpose of this study was to use positron emission tomography (PET) with [ 11 C]PBR28, which binds to the neuroinflammation marker translocator protein 18 kDa (TSPO), to compare the level of TSPO between individuals with depression and control subjects. Ten individuals who were in an acute episode of major depression and 10 control subjects matched for TSPO genotype and other characteristics had a PET scan with arterial input function to quantify levels of TSPO in brain regions of interest (ROIs). Total volume of distribution (V T ) of [ 11 C]PBR28 was used as a measure of total ligand binding. The primary outcome was the difference in V T between the two groups; this was assessed using a linear mixed model with group as a between-subject factor and region as a within-subject factor. There was no statistically significant difference in [ 11 C]PBR28 binding (V T ) between the two groups. In fact, 7 of 10 individuals with depression had lower [ 11 C]PBR28 binding in all ROIs compared to their respective genotype-matched control subjects. Future studies are needed to determine whether individuals with mild-to-moderate depression have lower TSPO levels and to assess whether individuals with severe depression and/or with elevated levels of systemic inflammation might have higher TSPO levels than control subjects.
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Introduction
Depression is a debilitating disease that has a 1-year prevalence of 4-5% in men and 8-9% in women, and a lifetime prevalence of 16.5% (www.nimh.nih.gov/statistics). The etiology of depression is not well understood; however, genetic factors, exposure to stress, and impairment in neuroplasticity are all believed to play a role (Krishnan and Nestler, 2010; Wager-Smith and Markou, 2011) . In addition, a large body of literature suggests that immune mediators may contribute to depression (WagerSmith and Markou, 2011). For instance, some individuals with depression have increased blood levels of the inflammatory cytokines tumor necrosis factor alpha (TNFa) and interleukin 6 (IL-6) (Dowlati et al., 2010) ; however, it is not known whether this is a result of depression or potentially a contributing cause. In animal models, stress can increase systemic inflammation and neuroinflammation, including activation of microglia (Sugama et al., 2009; Hinwood et al., 2012) . In individuals with multiple sclerosis, stress was associated with new inflammatory brain lesions as detected by magnetic resonance imaging (MRI), whereas stress management was shown to reduce such lesions (Mohr et al., 2012) . Therefore, it is possible that the stress associated with repeated depressive episodes (or the stress that contributes to causing depressive episodes) leads to systemic inflammation, rather than the other way around. Arguing against this notion is the fact that successful treatment of depression with antidepressant medications does not lead, at least in the short term, to normalization of increased levels of inflammatory cytokines, as shown in a meta-analysis (Hannestad et al., 2011a) . Moreover, a recent trial suggested that anti-TNFa therapy with infliximab may ameliorate depressive symptoms in patients with levels of high-sensitivity C-reactive protein (hsCRP) >5 mg/L (Raison et al., 2012) , an inflammatory marker that is associated with depression (WiumAndersen et al., 2012) . This suggests that systemic inflammation may contribute to producing depressive symptoms. In support of this, a large body of literature shows that inflammatory stimuli can produce depressive-like symptoms in individuals without depression (Wright et al., 2005; Capuron et al., 2007 Capuron et al., , 2009  
